Drug Profile
Research programme: Ebola virus vaccine - Pentamer Pharmaceuticals
Alternative Names: Ebola DNA vaccine - Pentamer Pharmaceuticals; Ebola peptide vaccine - Pentamer PharmaceuticalsLatest Information Update: 06 Aug 2023
Price :
$50
*
At a glance
- Originator Pentamer Pharmaceuticals
- Class DNA vaccines; Peptide vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Ebola virus infections
Most Recent Events
- 06 Aug 2023 Discontinued - Preclinical for Ebola virus infections in USA (PO)
- 28 Nov 2018 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA (PO)
- 16 Oct 2014 Research programme: Ebola virus vaccine - Pentamer Pharmaceuticals is available for licensing as of 16 Oct 2014. http://www.pentamerpharma.com/